First studies underway at Mayday University Hospital!

Posted:
16
June 2005

We are delighted to have started conducting clinical trials within Mayday University Hospital's flagship facilities. Construction and development of the new purpose built units was completed in May, allowing Early Phase studies to commence and complement our other premises within St George's University London.

“We moved into our new premises in early May and we are now conducting clinical research within the Mayday units. The transition has been very smooth and we are already reaping the rewards of the enhanced set-up.”— Dr Jörg Täubel, Managing Director, Richmond Pharmacology.
“Running clinical trials in our Mayday unit is proving very advantageous. The additional capacity we can manage up to 100 in-patients simultaneously. Our facilities are designed specifically for client and panel requirements and this helps trial conduct to run efficiently. For example, we now have dedicated monitoring facilities on the ward, with adjoining offices for a variety of support functions. I'm looking forward to taking full advantage of these facilities.”— Jean Van Wyk, Senior Research Physician and Head of Medical Department.
“The facilities have been purpose built, and this provides a tremendous advantage for our volunteers. The wards and recreational areas are spacious and comfortable. Volunteer feedback on the internet and lounge rooms has been very favourable. And, of course, it's reassuring to work within the acute environment of the NHS Trust.”— Dr Ulrike Lorch, Medical Director.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more